- Home
- CTOS vs AUPH Comparison
CTOS vs AUPH Comparison
Compare CTOS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTOS | AUPH |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTOS | AUPH |
|---|---|---|
| Price | $10.27 | $16.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $13.17 | ★ $18.29 |
| AVG Volume (30 Days) | ★ 983.5K | 865.9K |
| Earning Date | 10-26-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.04 | ★ 0.76 |
| Revenue | ★ $1,943,957,000.00 | $283,055,000.00 |
| Revenue This Year | $8.91 | $16.65 |
| Revenue Next Year | $6.09 | $17.73 |
| P/E Ratio | $250.75 | ★ $21.45 |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $5.18 | $13.52 |
| 52 Week High | $12.23 | $19.25 |
Technical Indicators
Market Signals| Indicator | CTOS | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 43.46 |
| Support Level | $9.07 | $15.67 |
| Resistance Level | $11.00 | $16.48 |
| Average True Range (ATR) | 0.64 | 0.55 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 76.61 | 15.30 |
Price Performance
Historical ComparisonAbout CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.